Will supply more doses of AstraZeneca vaccine to UK later, says Serum

Senior officials in New Delhi confirmed that there was no ban on exports from India, and no plans to do so either.

Serum
An employee stacks packed vials of Covishield at the Serum plant in Maharashtra (Photo: Bloomberg)
Sohini Das Mumbai
2 min read Last Updated : Mar 19 2021 | 10:34 PM IST
The Serum Institute of India (SII) has said it will try to supply more doses of the AstraZeneca vaccine to the UK later based on the requirements in India. This comes despite a controversy surrounding supplies of the vaccines.
 
A company spokesperson said, “Five million doses had been delivered a few weeks ago to the UK and we will try to supply more later, based on the current situation and requirement for the government immunisation programme in India.”
 
A London-based daily had quoted SII Chief Executive Officer Adar Poonawalla saying exports to the UK would resume once the company had green light (from the Indian government) to do so. 
 
Senior officials in New Delhi confirmed that there was no ban on exports from India, and no plans to do so either.
 
Agencies had reported that British Prime Minister Boris Johnson has said that a delay in the supply of Covid vaccine from the SII in India to Britain was due to technical issues and not because of any intervention by India.
 
SII is prioritising the needs for India as the national immunisation programme here is gaining momentum. The firm has recently got orders to deliver 100 million doses to the Government of India.
 
A source clarified that the 10 million doses that SII is supplying to the UK is to assist the country in its vaccination drive. Of this, 5 million have already been exported, and the remaining would go later depending on the domestic requirements.
 
 Recently, Poonawalla had said in a tweet: “Dear countries and governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best.”


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Serum Institute of IndiaAstraZenecaCoronavirus VaccinePharma Companies

Next Story